Anaplastic large cell lymphoma
Active Research Protocols
- 03-C-0304 – Pilot Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas
- 04-C-0173 – Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas
- 10-C-0178 – A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
- 93-C-0133 – Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's Lymphoma
NOTE: PDF documents require the freeAdobe Reader.
This page was last updated: January 24, 2014